Pfizer Inc.

Recent Events

News & Analysis

patient and pfizer inc. - All News and Analysis

• NEJM: Foreign Drug Trials Could Hurt U.S. Patients

  BNET - 2009-02-19

  The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...

  Tags: U.S., China, India, Patient, Vaccine, Pfizer Inc., Drug Company, Clinical Trial, Trial, Argentine Authority, GSK, Healthcare, Jim Edwards

• Federal Prosecutor Warns Drug Companies on Off-Label Promotion: "This Must Stop''

  BNET - 2009-01-27

  Laurie Magid, the acting U.S. attorney for Pennsylvania's Eastern District, has written a strongly worded warning to drug companies that they must stop promoting off-label uses for drugs or face the consequences. The warning comes after both Pfizer and Eli Lilly paid record fines for off-label promotion...

  Tags: FDA, Patient, Pfizer Inc., Cephalon Inc., Federal Government, Sales Strategy, Government, Sales, Jim Edwards

• The Pfizer-Shire Deal Worst-Case Scenario

  BNET - 2009-01-07

  Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...

  Tags: Patient, Medicaid, Pfizer Inc., Generic, Shire, ADHD, Vyvanse, Barr, Cola, Healthcare, Jim Edwards

• Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

  - 2008-05-30

  WHAT: Pfizer Oncology will host a journalist briefing at the American Society of Clinical Oncology ASCO Annual Meeting on Sunday, June 1, 2008, highlighting key data presentations from a variety ...

  Tags: patient, Pfizer Inc.

• Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma

  - 2008-04-01

  NEW YORK -- Pfizer Inc announced today the discontinuation of a Phase III clinical trial (A3671009), of single-agent tremelimumab (CP-675,206) in patients with advanced melanoma, after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.

  Tags: patient, Pfizer Inc.

• Pfizer, Novartis, Wyeth, GSK, Bayer to Discuss Latest Tactics and Strategies to Improve Patient Compliance and Communication.

  - 2008-01-11

  LONDON, January 11 /PRNewswire/ -- eyeforpharma, the global source of information and education for the pharmaceutical industry, announced today that the 5th annual Patient Compliance & Communication conference, London, 11-12 June 2008 has se LONDON, January 11 /PRNewswire/ -- ...

  Tags: Bayer AG, Novartis AG, patient, Pfizer Inc., strategy, Wyeth

• Licensing Executives Society Announces 2007 Deals of Distinction Awards(TM)

  - 2007-10-17

  Intellectual property IP -- specifically patents, copyrights, trademarks and trade secrets -- is the fundamental unit of innovation in our knowledge-based economy. Agreements that facilitate transfer of IP help establish the value for innovation. License agreements also help secure investments to advance research and realize the promise of innovation for...

  Tags: Benefits, brand, Branding, HEALTHCARE, Japan, Johnson & Johnson, Lockheed Martin Corp., MARKETING, Mayo Clinic, patient, Pfizer Inc., SOFTWARE

• Pfizer and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients with Diabetes

  - 2007-09-21

  AMSTERDAM, Netherlands -- Pfizer and the European Foundation for the Study of Diabetes EFSD announced today, at the European Association for the Study of Diabetes EASD Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk...

  Tags: patient, Pfizer Inc.

• Pfizer Proves It Can Do More with Lipitor - Protecting Vital Access to Patients at the Heart of Winning Managed Care Strategy

  - 2007-08-30

  FEASTERVILLE, Pa. -- With Lipitor's formulary access constricting due to generic competition and looming patent expiration, Pfizer aims to extend the health of its flagship cholesterol reducer with an aggressive promotional regimen rivaling that of a new drug in its launch phase. During the first half of 2007 Lipitor was...

  Tags: Lipitor, Microsoft Access, patient, Pfizer Inc., strategy

• Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says

  - 2007-06-03

  Study Shows Quarterly Dosing of CP-675,206 is Well Tolerated, Can Induce Durable Responses to Treatment in Melanoma Patients With Most Responses Ongoing at Two to Three Years

  Tags: patient, Pfizer Inc.